Home › Research › Inflammation and the immune system
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology
Head E, Lott IT, Wilcock DM, Lemere CA.. Current Alzheimer research, 2016-01-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Chromosome 21, triplicated in Down Syndrome, contains several genes that are thought to play a critical role in the development of AD neuropathology. The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS. In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss.
What this study adds
Evidence grade: Low
This is a narrative review. This review explains that people with Down syndrome, who have an extra copy of chromosome 21 including the APP gene, develop amyloid plaques early and later develop other Alzheimer's-like brain changes such as tangles, inflammation, and neuron loss. It also notes evidence of compensatory responses that may delay dementia onset, but it does not report a treatment or cure.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Head, E., Lott, I. T., Wilcock, D. M., & Lemere, C. A. (2016). Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Current Alzheimer research. https://doi.org/10.2174/1567205012666151020114607
Vancouver
Head E, Lott IT, Wilcock DM, Lemere CA. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Current Alzheimer research. 2016. doi:10.2174/1567205012666151020114607. PMID: 26651341.
BibTeX
@article{head2016-26651341,
author = {Head, E. and Lott, I. T. and Wilcock, D. M. and Lemere, C. A.},
title = {{Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology}},
journal = {Current Alzheimer research},
year = {2016},
doi = {10.2174/1567205012666151020114607},
pmid = {26651341},
url = {https://doi.org/10.2174/1567205012666151020114607}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- The overexpression of the gene for the amyloid precursor protein (APP), on chromosome 21, leads to early onset beta-amyloid (Aβ) plaques in DS.
- In addition to Aβ accumulation, middle-aged people with DS develop neurofibrillary tangles, cerebrovascular pathology, white matter pathology, oxidative damage, neuroinflammation and neuron loss.
- There is also evidence of potential compensatory responses in DS that benefit the brain and delay the onset of dementia after there is sufficient neuropathology for a diagnosis of AD.
- This review describes some of the existing literature and also highlights gaps in our knowledge regarding AD neuropathology in DS.
Why it matters
This review explains that people with Down syndrome, who have an extra copy of chromosome 21 including the APP gene, develop amyloid plaques early and later develop other Alzheimer's-like brain changes such as tangles, inflammation, and neuron loss. It also notes evidence of compensatory responses that may delay dementia onset, but it does not report a treatment or cure.
Study details
- Evidence strengthLow
How this study scored 47/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Current Alzheimer research) |
| Journal's citation record | 1 / 4 | Current Alzheimer Research: journal h-index 119 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2016 — within 20 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 5 / 7 | Cited 290 times (OpenAlex, 2026-10-10) |
| Citations per year | 4 / 5 | 24.2 citations a year over 12 year(s) since 2016 |
| Impact for its field and year | 5 / 6 | Cited 31.9× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 4 / 6 | Cited by 34 other studies in this library |
| Still being cited | 3 / 4 | Cited 67 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author Cynthia Ann Lemere: h-index 67 (OpenAlex, whole career) |
| Institution's track record | 1 / 3 | University of Kentucky: institution h-index 824 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 26651341) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 47 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.2174/1567205012666151020114607
- PubMed: 26651341
- Original source →
- Free full text: PubMed Central →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 39.
Later studies that cite this one
33 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Inflammation and the immune system from nearby years
Also tagged “down”
527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.